Mengke Pharmaceutical

MicuRx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative anti-infective drugs to address the global challenge of multi-drug resistant (MDR) pathogens. The company's lead product, Contezolid (MRX-I), is a novel oxazolidinone antibiotic designed to minimize the myelosuppression and monoamine oxidase inhibition typically associated with this class; it received marketing approval in China in 2021 for complicated skin and soft tissue infections. MicuRx is also advancing Contezolid Acefosamil (MRX-4), an oral and intravenous prodrug, which is currently in global Phase 3 clinical trials for diabetic foot infections. Their pipeline extends to Gram-negative threats with MRX-8, a next-generation polymyxin derivative designed to reduce nephrotoxicity. Headquartered in Shanghai with R&D facilities in California, MicuRx is publicly traded on the Shanghai Stock Exchange STAR Market.